Results 131 to 140 of about 44,917 (208)

Zolbetuximab combined with chemotherapy in a patient with CLDN18.2-positive advanced gastric cancer undergoing hemodialysis: a case report. [PDF]

Front Oncol
Zhao Y, Jin Y, Fu L, Yao D, Zhou Z, Dong Y, Tan Y.   +6 more
europepmc   +1 more source

Cost-effectiveness of switching to S-1 after fluoropyrimidine-induced hand-foot syndrome or cardiovascular toxicity in the treatment of metastatic colorectal cancer. [PDF]

ESMO Open
van Eekelen R, Punt CJA, Kwakman JJM, Coupé VMH.   +3 more
europepmc   +1 more source

Efficacy of steroid-omitting antiemetic therapy in patients with advanced pancreatic cancer receiving nano-liposomal irinotecan plus fluorouracil and leucovorin. [PDF]

Support Care Cancer
Tokito Y, Ishigaki K, Nara K, Endo G, Nishio H, Fukuda K, Suzuki T, Sato Y, Takahara N, Boku N, Fujishiro M.   +10 more
europepmc   +1 more source

NALIRIFOX versus liposomal irinotecan plus fluorouracil/leucovorin as the second-line chemotherapy in gemcitabine refractory pancreatic adenocarcinoma: a real-world study. [PDF]

Ther Adv Med Oncol
Wong WZ, Chiang NJ, Lee KC, Yu HY, Tsai CJ, Hsu SJ, Lee PC, Chen MH, Huang HC, Li CP, Luo JC, Lee FY.   +11 more
europepmc   +1 more source

Predictors of prolonged progression-free survival in patients with unresectable or recurrent pancreatic cancer treated with nanoliposomal irinotecan with fluorouracil and folinic acid (NAPOLEON-2 study). [PDF]

Ther Adv Med Oncol
Kawaguchi Y, Hayashi K, Shimokawa M, Otsuka T, Nakazawa J, Shimokawa H, Shinohara Y, Koga F, Oza N, Oda H, Takeshita S, Arima S, Arita S, Nishikawa K, Otsu S, Taguchi H, Jikuya K, Sakai T, Ueda Y, Sakae T, Araki N, Sawase H, Ide Y, Kawahira M, Nio K, Shirakawa T, Mizuta T, Mitsugi K.   +27 more
europepmc   +1 more source

Molecular Determinants of Response and Rational Drug Combinations for Antibody-Drug Conjugates (ADCs) with Topoisomerase I (TOP1) Inhibitor Payloads. [PDF]

J Mol Biol
Pommier Y.
europepmc   +1 more source

Old tale new admirers, cetuximab maintenance in metastatic colorectal cancer: a systematic review and meta-analysis. [PDF]

Front Pharmacol
Yan Y, Lin Z, Yuan J, Gao W, Jiao C, Sun L, Sun X.   +6 more
europepmc   +1 more source

Comparative Efficacy of Fosnetupitant and Fosaprepitant for Delayed Vomiting in Patients Receiving Irinotecan-Oxaliplatin Combination Chemotherapy: A Retrospective Propensity Score-Matched Study. [PDF]

Cancer Manag Res
Maeda K, Kawada K, Hayashi T, Koyama S, Ishida T, Yoshioka T, Fukuda H, Horikawa I, Aizawa F, Niimura T, Yagi K, Goda M, Izawa-Ishizawa Y, Ishizawa K.   +13 more
europepmc   +1 more source

Phase II study of FOLFIRI with low-dose irinotecan plus ramucirumab as second-line treatment in Japanese patients with metastatic colorectal cancer (study rindo). [PDF]

Jpn J Clin Oncol
Hattori N, Nakayama G, Umeda S, Kishida T, Takeda S, Ezaka K, Tsutsuyama M, Sakai M, Hattori M, Ito T, Kanda M, Tanaka C, Murotani K, Ando M, Kodera Y.   +14 more
europepmc   +1 more source

Treatment patterns and clinical outcomes of metastatic gastric cancer in South Korea: real-world evidence from retrospective electronic medical records data. [PDF]

BMC Cancer
Kim E, Shin JY, Park S, Yoo JH, Kwon WS, Lee CK, Jung M, Kim HS, Chung HC, Rha SY.   +9 more
europepmc   +1 more source